Bad news for Galatasaray! Osimhen's MRI results are out.

Bad news for Galatasaray! Osimhen's MRI results are out.

19.11.2025 14:28

Galatasaray announced that Victor Osimhen's MRI scans revealed a moderate strain (strain and bleeding) in his left hamstring. The Nigerian player is expected to be sidelined for 2-3 weeks.

Super Lig giant Galatasaray made a statement regarding the health status of Victor Osimhen, who was injured during Nigeria's match against Congo. It was reported that the star striker has a moderate strain and bleeding in his left hamstring.

Bad news for Galatasaray! Osimhen's MRI results are in

In the statement made by Galatasaray regarding the issue, it was stated, "Our footballer Victor Osimhen has been diagnosed with a moderate strain (strain and bleeding) in his left hamstring during the MRI examinations conducted today at our sponsor hospital Acıbadem, and his treatment has begun. The MRI examinations of our national player Kaan Ayhan will be conducted this afternoon," the statement read.

Bad news for Galatasaray! Osimhen's MRI results are in

WILL HE MAKE IT TO THE DERBY?

The situation regarding Osimhen's return to the field at Galatasaray will depend on the speed of his recovery. The star striker will definitely not play in the league match against Gençlerbirliği. The speed of recovery will be decisive for the Champions League match against U.S. Gilloise.

Bad news for Galatasaray! Osimhen's MRI results are in

The biggest question mark is the critical Fenerbahçe derby to be played on December 1st in Kadıköy... It is aimed for Osimhen to be in the extended squad for this match, but whether he will play in the starting eleven or how many minutes he can wear the jersey will again be determined by doctors based on his recovery speed.

In order to provide you with a better service, we position cookies on our site. Your personal data is collected and processed within the scope of KVKK and GDPR. For detailed information, you can review our Data Policy / Disclosure Text. By using our site, you agree to our use of cookies.', '